ArticleAdvances in radiation oncology2026
Prospective Evaluation of Stereotactic Body Radiation Therapy for Reirradiation of Bone Metastases.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bone metastases are a common cause of morbidity among patients with cancer, and radiation therapy (RT) is efficacious for their palliation. However, symptomatic bone metastases can often occur in regions that have received prior RT, limiting doses that can be delivered safely. Stereotactic body radiation therapy (SBRT) enables the delivery of greater doses of RT to the tumor while minimizing reirradiation dose to critical organs at risk. Methods and Materials: In this prospective, multi-institutional phase 2 trial, 45 patients with bone metastasis in a previously irradiated region were treated with SBRT from February 2017 to November 2021. The primary endpoint was local control at 6 months post RT; secondary aims were rates of acute and chronic toxicity, time to local progression, local progression rate, progression-free survival, and overall survival. Results: The median age of participants was 62.6 years, and most were male (75.6%). The most common primary tumor types were as follows: prostate (13/45, 28.9%), lung (8/45, 17.8%), and renal cell (5/45, 11.1%). The majority received reirradiation to a spinal lesion (35/45, 77.7%). The most common dose prescriptions were 30 Gy in 5 fractions (24/45, 53.3%) and 35 Gy in 5 fractions (11/45, 24.4%). At 6 months, 42 of 45 treated sites were locally controlled, whereas 3 had progressed at a median of 3.6 months. The local progression-free rate was 89.9% at 2 years. Overall survival was 52% at 2 years. Acute toxicities occurred in 46.7%, most commonly fatigue, nausea, and pain flare; all were grade 1 or 2. In total, 8.9% of participants experienced chronic toxicities, including vertebral fracture and pain flare, all grade 1 or 2 with no myelopathies. Conclusions: This prospective study of SBRT for reirradiation of bone metastases demonstrated effective local control and reasonable rates of acute and chronic toxicities. Additional research is needed to further ascertain long-term efficacy and treatment-related toxicities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.